Roivant Sciences Ltd.和Priovant宣布Brepocitinib治疗皮肌炎的3期Valor研究在52周安慰剂对照试验中获得积极结果

美股速递
Sep 17

Roivant Sciences Ltd.和Priovant宣布Brepocitinib治疗皮肌炎的3期Valor研究在52周安慰剂对照试验中获得积极结果

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10